Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-CD47M in Advanced Solid Tumors
NCT03957096Phase 1Terminated
- Sponsor
- Seagen Inc.
- Start
- Jul 2019
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SGN-CD47M in soft tissue sarcoma (STS), colorectal carcinoma (CRC), head and neck squamous cell carcinoma (HNSCC) and 6 more, sponsored by Seagen Inc. Primary endpoints: Number of patients with adverse events at 24 months, Number of patients with laboratory abnormalities at 24 months and 1 more. Started Jul 2019; status: terminated.
02
Drugs
SGN-CD47M
03
Conditions
soft tissue sarcoma (STS)colorectal carcinoma (CRC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung carcinoma (NSCLC)breast carcinoma
Beyond the preview
Go deeper on NCT03957096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03957096.